Mather Group LLC. Acquires 58 Shares of Cencora, Inc. (NYSE:COR)

Mather Group LLC. boosted its holdings in Cencora, Inc. (NYSE:COR) by 2.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,615 shares of the company’s stock after buying an additional 58 shares during the quarter. Mather Group LLC.’s holdings in Cencora were worth $588,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in COR. Czech National Bank raised its holdings in Cencora by 12.6% in the 3rd quarter. Czech National Bank now owns 35,536 shares of the company’s stock valued at $7,998,000 after buying an additional 3,990 shares during the last quarter. GAMMA Investing LLC increased its position in Cencora by 22.6% during the 3rd quarter. GAMMA Investing LLC now owns 3,385 shares of the company’s stock valued at $762,000 after purchasing an additional 623 shares during the period. Dynamic Advisor Solutions LLC increased its position in Cencora by 15.2% during the 3rd quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company’s stock valued at $262,000 after purchasing an additional 154 shares during the period. Gratus Wealth Advisors LLC increased its position in Cencora by 2.4% during the 3rd quarter. Gratus Wealth Advisors LLC now owns 8,974 shares of the company’s stock valued at $1,970,000 after purchasing an additional 214 shares during the period. Finally, Strategic Wealth Partners Ltd. increased its position in Cencora by 2.7% during the 3rd quarter. Strategic Wealth Partners Ltd. now owns 23,657 shares of the company’s stock valued at $5,325,000 after purchasing an additional 624 shares during the period. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Wells Fargo & Company increased their target price on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. UBS Group increased their target price on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Mizuho assumed coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price for the company. Barclays increased their target price on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Robert W. Baird raised their price objective on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $278.40.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,187 shares of company stock worth $17,790,912. Corporate insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $253.53 on Thursday. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26. The business’s fifty day moving average is $239.08 and its 200 day moving average is $236.51. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The stock has a market cap of $49.00 billion, a P/E ratio of 33.76, a P/E/G ratio of 1.59 and a beta of 0.49.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 266.62% and a net margin of 0.51%. Sell-side analysts anticipate that Cencora, Inc. will post 15.32 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.87%. Cencora’s dividend payout ratio is currently 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.